Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience

Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group

doi:10.1093/oncolo/oyab031

Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience

Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Histiocytic disorders pose significant diagnostic and management challenges for the clinicians due to diverse clinical manifestations and often non-specific histopathologic findings. Herein, we report the tumor board experience from the first-of-its-kind Histiocytosis Working Group (HWG). Materials and Methods: The HWG was established in June 2017 and consists of experts from 10 subspecialties that discuss cases in a multidisciplinary format. We present the outcome of tumor board case discussions during the first 2 years since its inception (June 2017-June 2019). Results: Forty cases with a suspected histiocytic disorder were reviewed at HWG during this time period. Average number of subspecialties involved in HWG case discussion was 5 (range, 2-9). Histiocytosis Working Group tumor board recommendations led to significant changes in the care of 24 (60%) patients. These included change in diagnosis (n = 11, 27%) and change in treatment (n = 13, 33%). Conclusion: Our report highlights the feasibility of a multidisciplinary tumor board and its impact on outcomes of patients with histiocytic disorders.

Original language	English (US)
Pages (from-to)	144-148
Number of pages	5
Journal	Oncologist
Volume	27
Issue number	2
DOIs	https://doi.org/10.1093/oncolo/oyab031
State	Published - Feb 2022

Keywords

Erdheim–Chester disease
giant cell tumor of tendon sheath
histiocytes
immunoglobulin G4-related disease
osteopoikilosis

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/oncolo/oyab031

Cite this

@article{0f188a66033a49a58f6e6ee9e08a23f8,

title = "Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience",

abstract = "Introduction: Histiocytic disorders pose significant diagnostic and management challenges for the clinicians due to diverse clinical manifestations and often non-specific histopathologic findings. Herein, we report the tumor board experience from the first-of-its-kind Histiocytosis Working Group (HWG). Materials and Methods: The HWG was established in June 2017 and consists of experts from 10 subspecialties that discuss cases in a multidisciplinary format. We present the outcome of tumor board case discussions during the first 2 years since its inception (June 2017-June 2019). Results: Forty cases with a suspected histiocytic disorder were reviewed at HWG during this time period. Average number of subspecialties involved in HWG case discussion was 5 (range, 2-9). Histiocytosis Working Group tumor board recommendations led to significant changes in the care of 24 (60%) patients. These included change in diagnosis (n = 11, 27%) and change in treatment (n = 13, 33%). Conclusion: Our report highlights the feasibility of a multidisciplinary tumor board and its impact on outcomes of patients with histiocytic disorders.",

keywords = "Erdheim–Chester disease, giant cell tumor of tendon sheath, histiocytes, immunoglobulin G4-related disease, osteopoikilosis",

author = "{Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group} and Gaurav Goyal and Young, {Jason R.} and Abeykoon, {Jithma P.} and Shah, {Mithun V.} and {Nora Bennani}, N. and Sartori-Valinotti, {Julio C.} and Robert Vassallo and Ryu, {Jay H.} and {Oliver Tobin}, W. and Koster, {Matthew J.} and Davidge-Pitts, {Caroline J.} and Aishwarya Ravindran and Rech, {Karen L.} and Go, {Ronald S.}",

note = "Funding Information: The study was supported in part by the University of Iowa/ Mayo Clinic Lymphoma SPORE CA97274 and the Walter B. Frommeyer, Jr., Fellowship Award in Investigative Medicine, University of Alabama at Birmingham (G.G). Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press.",

year = "2022",

month = feb,

doi = "10.1093/oncolo/oyab031",

language = "English (US)",

volume = "27",

pages = "144--148",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "2",

}

TY - JOUR

T1 - Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders

T2 - The Histiocytosis Working Group experience

AU - Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group

AU - Goyal, Gaurav

AU - Young, Jason R.

AU - Abeykoon, Jithma P.

AU - Shah, Mithun V.

AU - Nora Bennani, N.

AU - Sartori-Valinotti, Julio C.

AU - Vassallo, Robert

AU - Ryu, Jay H.

AU - Oliver Tobin, W.

AU - Koster, Matthew J.

AU - Davidge-Pitts, Caroline J.

AU - Ravindran, Aishwarya

AU - Rech, Karen L.

AU - Go, Ronald S.

N1 - Funding Information: The study was supported in part by the University of Iowa/ Mayo Clinic Lymphoma SPORE CA97274 and the Walter B. Frommeyer, Jr., Fellowship Award in Investigative Medicine, University of Alabama at Birmingham (G.G). Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press.

PY - 2022/2

Y1 - 2022/2

N2 - Introduction: Histiocytic disorders pose significant diagnostic and management challenges for the clinicians due to diverse clinical manifestations and often non-specific histopathologic findings. Herein, we report the tumor board experience from the first-of-its-kind Histiocytosis Working Group (HWG). Materials and Methods: The HWG was established in June 2017 and consists of experts from 10 subspecialties that discuss cases in a multidisciplinary format. We present the outcome of tumor board case discussions during the first 2 years since its inception (June 2017-June 2019). Results: Forty cases with a suspected histiocytic disorder were reviewed at HWG during this time period. Average number of subspecialties involved in HWG case discussion was 5 (range, 2-9). Histiocytosis Working Group tumor board recommendations led to significant changes in the care of 24 (60%) patients. These included change in diagnosis (n = 11, 27%) and change in treatment (n = 13, 33%). Conclusion: Our report highlights the feasibility of a multidisciplinary tumor board and its impact on outcomes of patients with histiocytic disorders.

AB - Introduction: Histiocytic disorders pose significant diagnostic and management challenges for the clinicians due to diverse clinical manifestations and often non-specific histopathologic findings. Herein, we report the tumor board experience from the first-of-its-kind Histiocytosis Working Group (HWG). Materials and Methods: The HWG was established in June 2017 and consists of experts from 10 subspecialties that discuss cases in a multidisciplinary format. We present the outcome of tumor board case discussions during the first 2 years since its inception (June 2017-June 2019). Results: Forty cases with a suspected histiocytic disorder were reviewed at HWG during this time period. Average number of subspecialties involved in HWG case discussion was 5 (range, 2-9). Histiocytosis Working Group tumor board recommendations led to significant changes in the care of 24 (60%) patients. These included change in diagnosis (n = 11, 27%) and change in treatment (n = 13, 33%). Conclusion: Our report highlights the feasibility of a multidisciplinary tumor board and its impact on outcomes of patients with histiocytic disorders.

KW - Erdheim–Chester disease

KW - giant cell tumor of tendon sheath

KW - histiocytes

KW - immunoglobulin G4-related disease

KW - osteopoikilosis

UR - http://www.scopus.com/inward/record.url?scp=85131217775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131217775&partnerID=8YFLogxK

U2 - 10.1093/oncolo/oyab031

DO - 10.1093/oncolo/oyab031

M3 - Article

C2 - 35641201

AN - SCOPUS:85131217775

SN - 1083-7159

VL - 27

SP - 144

EP - 148

JO - Oncologist

JF - Oncologist

IS - 2

ER -

Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this